Major Adverse Cardiac Events at Follow-Up After Bare-Metal Stenting Versus Drug-Eluting Stenting in ST-Elevated Myocardial Infarction.
Am J Cardiol. 2009 Jun 15;103(12):1672-4
Authors: Pierre-Louis B, Aronow WS, Palaniswamy C, Singh T, Ahn C, Asija A, Weiss MB, Kalapatapu K, Pucillo AL, Monsen CE
After thrombolytic therapy with tenecteplase for ST-segment elevation acute myocardial infarction, 376 patients were transferred from their hospital to Westchester Medical Center for percutaneous coronary intervention with stenting. Of 376 patients, 102 (27%) received bare-metal stents and 274 (73%) received drug-eluting stents with sirolimus-eluting or paclitaxel-eluting stents. At 43 months of follow-up, major adverse cardiac events occurred in 25 (25%) of 102 patients treated with bare-metal stents versus 40 (15%) of 274 patients treated with drug-eluting stents (p = 0.024). Cox regression analysis showed that significant independent prognostic factors for major adverse cardiac events were previous coronary artery bypass surgery (hazard ratio 2.2, p = 0.019), width of stent (hazard ratio 0.44, p = 0.006), and bare-metal stent (hazard ratio 1.8, p = 0.019). In conclusion, patients with bare-metal stents had a 1.8 times greater risk of developing major adverse cardiac events than did those using drug-eluting stents after controlling the confounding effects of previous coronary artery bypass surgery and stent width.
PMID: 19539074 [PubMed - in process]